Therefore, these findings suggested that VD may exert its therapeutic effect on NAFLD by reducing lipid uptake and elevating β-oxidation via the PPARα signaling pathway. The gene discussed is PPARA; the disease is metabolic dysfunction-associated steatotic liver disease.